Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Topoisomerase inhibitor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    7 result(s) found for: Topoisomerase inhibitor. Displaying page 1 of 1.
    EudraCT Number: 2021-001206-29 Sponsor Protocol Number: ShorTrip Start Date*: 2021-07-22
    Sponsor Name:Fondazione GONO
    Full Title: ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoadjuvant therapy for locally advanced rectal cancer.
    Medical condition: Locally advanced rectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038050 Rectal cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003836-22 Sponsor Protocol Number: FLG-V001 Start Date*: 2019-12-11
    Sponsor Name:HUS Helsinki University Hospital
    Full Title: TWO-STAGE, TWO-ARM, OPEN-LABEL PHASE II STUDY OF VENETOCLAX IN COMBINATION WITH AZACYTIDINE IN ACUTE MYELOID LEUKEMIA PATIENTS SELECTED USING EX VIVO DRUG SENSITIVITY SCREENING
    Medical condition: Acute myeloid leukemia in patients who are non-fit for standard induction therapy (except acute promyelocytic leukemia) and present with de novo, secondary, released or refractory AML
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005461-14 Sponsor Protocol Number: LD-VenEx Start Date*: 2022-04-20
    Sponsor Name:Righospitalet
    Full Title: The Nordic AML Group – LD-VenEx: PHASE II STUDY OF AZACITIDINE IN COMBINATION WITH LOW DOSE VENETOCLAX IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (INCLUDING EXPLORATORY EVALUATION OF EX VIVO DRUG SENS...
    Medical condition: Acute Myelogenic Leukemia is aggressiv leukemia and treatment i challenging specialy in patients not eligible for intensiv chemotherapy or relapsed after intensiv chemotherapy.In this study we will...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003061-19 Sponsor Protocol Number: CL1-65487-003 Start Date*: 2021-01-07
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Phase I / II, open label, dose escalation part (phase I) followed by non-comparative expansion part (phase II), multi-centre study, evaluating safety, pharmacokinetics and efficacy of S65487, a Bcl...
    Medical condition: Previously untreated Acute Myeloid Leukemia (AML)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) FR (Trial now transitioned) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004618-36 Sponsor Protocol Number: CTMX-2009-002 Start Date*: 2021-03-15
    Sponsor Name:CytomX Therapeutics, Inc.
    Full Title: A Phase 2, Open-Label Study to Evaluate the Safety and Antitumor Activity of CX-2009 in Advanced HR-Positive/HER2-Negative Breast Cancer and of CX-2009 as Monotherapy and in Combination with CX-072...
    Medical condition: HR-positive/HER2-negative breast cancer Triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000601-27 Sponsor Protocol Number: MERCURY Start Date*: 2022-09-27
    Sponsor Name:Fondazione GONO
    Full Title: Window-of-opportunity study of chemo-immunotherapy in patients with resectable Merkel Cell Carcinoma prior to surgery: the MERCURY trial
    Medical condition: The disease under clinical investigation is represented by resectable Merkel Cell Carcinoma (MCC), stage IIA-III (according to the AJCC staging system 8th edition). The study will include patients ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002169-16 Sponsor Protocol Number: ERASE-CRC Start Date*: 2022-06-10
    Sponsor Name:Fondazione GONO
    Full Title: EXPLOITING CIRCULATING TUMOUR DNA TO INTENSIFY THE POST-OPERATIVE TREATMENT OF STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS WITH ADJUVANT FOLFOXIRI AND/OR POST-ADJUVANT TRIFLURID...
    Medical condition: STAGE III AND HIGH-RISK STAGE II RESECTED COLON CANCER PATIENTS.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009954 Colon cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 14:21:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA